1. Academic Validation
  2. In vitro and in vivo interaction of moxidectin with BCRP/ABCG2

In vitro and in vivo interaction of moxidectin with BCRP/ABCG2

  • Chem Biol Interact. 2009 Jun 15;180(1):106-12. doi: 10.1016/j.cbi.2009.02.009.
Miriam Perez 1 Alba G Blazquez Rebeca Real Gracia Mendoza Julio G Prieto Gracia Merino Ana I Alvarez
Affiliations

Affiliation

  • 1 Departamento de Ciencias Biomedicas - Fisiologia, Facultad de Veterinaria, Universidad de Leon, Leon, Spain.
Abstract

The study characterizes the interaction between BCRP/ABCG2 and moxidectin by means of cellular transport, and pharmacokinetic studies in Bcrp1 (-/-) and wild-type mice. Milbemycin moxidectin ([(3)H]-moxidectin) was tested for its ability to be transported across MCDK-II epithelial monolayer cultures transfected with BCRP. In a second approach, accumulation assays by BCRP-expressing Xenopus laevis oocytes were carried out. Finally, pharmacokinetic studies were performed in order to establish the role of the transporter in milk secretion and tissue distribution. The efflux was negligible in polarized cells but moxidectin was efficiently transported in BCRP-expressing X. laevis oocytes. The transport was blocked by an acridone derivative, a novel BCRP Inhibitor. Moxidectin secretion into breast milk was decreased in Bcrp1-knockout mice and the milk to plasma ratio was 2-fold higher in wild-type mice after i.v. administration. Drug accumulation in intestinal content, bile, and intestine was higher in wild-type mice but the plasma concentration was not different. Moxidectin is identified as a BCRP substrate since its Bcrp1-mediated secretion into breast milk and the involvement of Bcrp1 in intestinal and bile secretion has been demonstrated. This interaction has pharmacokinetic and toxicological consequences. The most important toxicological consequences of the interaction between BCRP and moxidectin may be related with the presence of drug residues in milk.

Figures
Products